|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Chiesi Farmaceutici SpA And Novartis Pharma AG (NVS) Sign International Licensing Agreement For Formoterol Modulite® HFA
10/19/2005 5:12:34 PM
Chiesi Farmaceutici S.p.A. and Novartis Pharma AG have signed an international licensing and supply agreement for Chiesi’s Formoterol Modulite®, an HFA-based pressurised metered-dose inhaler (pMDI) product. Under the agreement, Novartis will have semi-exclusive promotion, sales and distribution rights for the product, following approval, in Denmark, France, Germany, Greece, Netherlands, Republic of South Africa, Spain, Switzerland and Turkey. Chiesi will supply Novartis with the finished product. A previous agreement for commercialisation of the product in Italy was signed last year.
|
|
|
|
|
|
|
|
|
|
|